Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Fixed Sequence Crossover Study to Investigate the Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin, a Breast Cancer Resistance Protein Substrate, in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase I, Open-label, Fixed Sequence Crossover Study to Investigate the Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin, a Breast Cancer Resistance Protein Substrate, in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin (Primary) ; Sotorasib (Primary)
  • Indications Brain metastases; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Amgen

    • Most Recent Events

    • 24 Mar 2023 Results assessing effect of coadministration of sotorasib on the pharmacokinetics of rosuvastatin, in healthy subjects, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 15 Oct 2021 Status changed from active, no longer recruiting to completed.
    • 05 Oct 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top